Intrinsic growth heterogeneity of mouse leukemia cells underlies differential susceptibility to a growth-inhibiting anticancer drug.
Cancer cell populations consist of phenotypically heterogeneous cells. Growing evidence suggests that pre-existing phenotypic differences among cancer cells correlate with differential susceptibility to anticancer drugs and eventually lead to a relapse. Such phenotypic differences can arise not only...
Main Authors: | Akihisa Seita, Hidenori Nakaoka, Reiko Okura, Yuichi Wakamoto |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2021-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0236534 |
Similar Items
-
Scale invariance of cell size fluctuations in starving bacteria
by: Takuro Shimaya, et al.
Published: (2021-11-01) -
A unified framework for measuring selection on cellular lineages and traits
by: Shunpei Yamauchi, et al.
Published: (2022-12-01) -
Imiquimod inhibits growth and induces differentiation of myeloid leukemia cell lines
by: Eva Villamón, et al.
Published: (2018-01-01) -
Removal of bacterial growth inhibition of anticancer drugs by using complexation materials
by: Sangnier Maïté, et al.
Published: (2020-05-01) -
Targeting NRF2 uncovered an intrinsic susceptibility of acute myeloid leukemia cells to ferroptosis
by: Xin Liu, et al.
Published: (2023-05-01)